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Defining Neoepitopes that Contribute to Tumor Immunity 
 
 
Over the last half century, it has become well established that cancer can elicit a host immune 
response that can target the tumor with high specificity. Only within the last decade, with the 
advances in gene sequencing and bioinformatics approaches, are we now on the forefront of 
harnessing the host’s immune system to fight cancer. Recently, many great strides have been 
taken towards understanding effective tumor specific major histocompatibility complex I 
restricted epitopes, or neoepitopes.  However, many fundamental questions still remain that must 
be addressed before this knowledge can live up to its full potential in the clinic. Issues ranging 
from the accurate identification all the somatic mutations in a given tumor sample to the 
prediction of the “best” neoepitopes and translation of that information into the most effective 
treatment illustrate the hurdles that remain. In this thesis, I present results of an exhaustive and 
exhausting study where I have tested hundreds of long peptides each containing a single 
nucleotide variant (SNV) (with the mutation in the center of the peptide) for their ability to elicit 
tumor rejection and independently, CD8
+
 T cell response. I observe that (i) about 7% of all SNVs 
lead to generation of peptides that can mediate tumor rejection to any significant degree; (ii) each 
peptide alone elicits a modest protection, and a combination elicits stronger protective immunity; 
(iii) most  neoepitopes that elicit tumor rejection have poor binding affinity for MHC I and have 
positive values for Differential Agretopic Index; (iv) even though the protective responses are 
CD8-mediated, there is no correlation between a neoepitope’s ability to elicit a measureable CD8 
response and tumor rejection; (v) and lastly that the neoepitopes elicit a variety of T effector cell 
phenotypes and, in a preliminary analysis, one particular CD8 T cell phenotype is a better 
predictor of tumor rejection. Through ongoing and subsequent future work, the aim is to truly 
understand what makes a good neoepitope and in turn translate this knowledge into effective 
treatments. 
 
 
 
(Modified from Brennick CA, George MM, Corwin WL, Srivastava PK, Ebrahimi-Nik. 
Immunotherapy. 2017 Mar, 9(4):361-371. doi 10.2217/imt-2016-0146.)  
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Introduction 
It is now appreciated that cancer is a profoundly patient specific disease, where no two tumors 
are alike. The foundation of this insight stemmed from the early murine work of Ludwig Gross
1
, 
Prehn and Main
2
, and George and Eva Klein
3
 that clearly demonstrated the tumor 
immunogenicity is not only patient specific but inherently specific to the individual tumor itself. 
Continued cancer research in areas such as immunology, genomics, biochemistry, metabolomics, 
etc. have further enhanced our appreciation of the vast complexity of this malady.   
 
A critical realization was that of the immense heterogeneity not just between patients diagnosed 
with the same type of cancer but also within a single patient’s lesion(s)4,5.  This heterogeneity 
has made conventional cancer therapies limited in their success to treat all cancers due to each 
tumor’s individuality.  Further, the concept of immunoediting6, or the selective pressure of the 
immune system to drive tumor evolution, has helped as a framework to understand not only 
tumor development but also treatment resistance and metastasis. In response to these insights, 
considerable efforts have begun to develop and adopt “precision medicine” or cancer therapies 
that aim to treat in a patient specific manner. To this end, a number of cancer immunotherapies 
have been developed that look to exploit the immune system’s exquisite ability to selectively 
target cancer cells
7–9
. While considerable gains have been made with regard to treatment 
outcomes for many patients, there still remains a fundamental deficiency in our knowledge of the 
precise immunological underpinnings behind this tumor specificity observed over a half a 
century ago. 
 
3 
 
Since the time it was initially proposed over two decades ago
10
, it has now become well 
established that somatic, or so-called passenger, mutations within the tumor give rise to new 
epitopes, or neoepitopes.  Considerable experimental evidence for this idea was obtained starting 
in the 1990’s (Table 1). Further, evidence supports that neoepitopes are recognized by the 
adaptive immune system as “mutated self” and serve as the means by which immune systems 
can differentiate cancer from normal cells
11
. Thus, neoepitopes make strong candidates for 
personalized cancer immunotherapy vaccines. With the recent advancements in genomic 
sequencing and bioinformatic approaches, the feasibility of personalized therapy in the clinical 
setting is now on the forefront.  However, there are still major obstacles that need to be 
addressed. To this day, most of the putative neoepitopes identified have not worked in rejecting 
tumor, with an average of less than 7.5% of predicted neoepitopes being capable of eliciting a 
tumor specific immune response
12
. Issues ranging from the accurate identification all the somatic 
mutations in a given tumor sample to the prediction of the “best” neoepitopes and translation of 
that information into the most effective treatment illustrate the hurdles that remain. Here, I will 
discuss these challenges and the work being done to address them in an effort to truly understand 
what makes a good neoepitope and how best to translate this knowledge into effective treatment 
modalities. 
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a
The residues modified by the mutation are indicated in red 
Gene/Protein Tumor Restricting 
MHC 
Peptidea Codon Elicits protective 
tumor immunity? 
Ref 
L9 ribosomal 
protein 
6123A 
Squamous Ca 
IEk DFNHINVELSHLGK 47 YES 13 
P68 RNA helicase 8101 
Squamous Ca 
Kb SNFVFAGI 551 Not testable, since 
tumor is a regressor 
14 
P53 Meth A 
fibrosarcoma 
Kd KYICNSSCM 234 YES 15 
ERK2 CMS5 
fibrosarcoma 
Kd LQYIHSANVL 136 YES 16 
L11 ribsomal 
protein 
Meth A 
fibrosarcoma 
IEd EYELRKHNFSDTG 
 
97 YES 17 
Akt 5’ 
untranslated 
region 
RLM1 
leukemia 
Ld IPGLPLSL 5’ untranslated YES 18,19 
Table 1 | Tumor-specific antigens of mouse tumors 
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cells, natural killer cells (NK) and dendritic cells (DCs).  Cytotoxic CD8
+
 T cells (CTLs) are the 
most potent cell type which when activated, are able to recognize tumor specific antigens and 
distinguish between normal and cancerous cells. To achieve this tumor specific killing, cancer 
vaccines containing MHC class I restricted epitopes should activate CD8
+
 T cells to specifically 
kill cancerous cells
20,21
. This involves a number of steps which are summarized as follows
22
. 
Degradation of ubiquitinated proteins by the proteasome in the cytosol, chaperoning of peptides 
by heat shock protein (HSP) 90 in the cytosol, active transport into endoplasmic reticulum (ER) 
by the transporter associated with antigen processing (TAP) and trimming to appropriate length 
by ERAP (ER aminopeptidases associated with antigen processing), loading onto the peptide 
binding cleft of the Class I MHC molecules with the help of chaperone proteins such as tapasin 
and transport to the cell surface which is then recognized by  the T cell receptor (TCR) on CD8
+
 
T cells. Neoepitopes are those peptides that arise from somatic mutations and recognized as 
different from self and presented by antigen presenting cells (APCs) such as DCs and the tumor 
cells itself
10
. Here cross presentation plays an important role as the APC is able to translocate 
exogenous antigens from the phagosome into the cytosol for proteolytic cleavage into MHC I 
epitopes by the proteasome
23
.  
 
Although the binding affinity of a peptide to MHC I is one of the most studied criteria in the 
search for neoepitopes, many other factors discussed here play an important role in whether a 
neoepitope is finally presented on the tumor cells and whether it is taken up by APCs and cross 
presented in order to activate neoepitope specific CD8
+
 T cells. Thus far, there are no reliable 
methods to accurately verify that in silico identified neoepitopes can actually elicit tumor 
regression or an immune response. As mentioned earlier, the peptides released by the proteasome 
7 
 
are transported to the ER from the cytosol by TAP. TAPPred is an on-line tool to predict binding 
affinity of peptides toward the TAP
24
. However, these tools for proteasomal cleavage or TAP 
binding and transport are limited and not accurate and most neoepitope prediction algorithms do 
not take into consideration this aspect
25
. Peptide trimming by ERAP is important for the loading 
of the correct sized peptide onto the peptide binding cleft of MHC I. Thus far, no prediction 
algorithm accurately incorporates the function of ERAP into predicting Class I restricted 
neoepitopes.  
 
It has been found, in various solid and hematological tumors, that some of the mutations occur in 
genes that are involved in antigen presentation. If this phenomenon occurs, then predicting 
neoepitopes for such tumors and using them for immunotherapy may not result in an immune 
response or tumor regression because the presentation of neoepitopes on the cell surface is 
defected.  The aberrations in the antigen presentation machinery range from defects in 
proteasomal subunit patterns, TAP, ERAP, other chaperone proteins and MHC I. They occur 
individually or in combination, and the frequency and nature of the defects vary according to the 
type of tumor. Defects in surface expression of MHC I molecules have been demonstrated in a 
large variety of human tumors
26
. As with the above-mentioned defects in the antigen presentation 
machinery, particularly loss of MHC I surface expression, the use of neoepitopes that, in silico, 
are predicted to be recognized by the immune system, based on MHC I structure, may not 
necessarily be presented by the tumor cells. In such cases, immunotherapy with these 
neoepitopes will not elicit an immune response or tumor regression. The addition of mass 
spectrometry (MS) may play a key role in prediction pipelines to account for the antigens that are 
actually presented on the tumor surface. It must be mentioned that this method has not yet 
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reached the level of being a high through put approach. However, improved sensitivity of MS in 
identifying tumor derived neoepitopes in patient’s tumors validated by neoepitope specific anti-
tumor immune response has been recently reported
27
.  
Another major aspect to eliciting a sufficient T cell response against a neoepitope, is its ability to 
bind its cognate TCR. It has been clearly demonstrated the TCR affinity and avidity are crucial 
to the T cell response amounted
28–30
. A great effort has been made to develop programs that can 
predict the ability of a MHC I with is peptide to bind to a known T cell receptor (TCR). Thus far 
the programs available are  CTLPan and NetCTLPan, but with a limited known TCR peptide 
MHC I interactions known, these programs are limited in there accuracy
31
. With new 
technologies emerging for the identification of TCRs to their cognate antigen these programs 
may become of great use to predict putative neoepitopes.  
The development of prediction algorithms or programs that incorporates not only the binding 
affinity of the neoepitope on MHC I but also the other steps of antigen processing, presentation 
and TCR recognition remains an important step towards improving the accuracy of predicting 
successful neoepitopes.  
 
Are we being misguided by binding affinity? 
In an effort to better predict putative neoepitopes from the large set of somatic mutations called 
for a given tumor, the criterion of binding affinity of a neoepitope to its cognate MHC I is 
applied. The most readily used technique for measuring binding affinity in vitro is by measuring 
the concentration of a given peptide needed to compete with a standardized peptide already 
bound to a given MHC I allele
32
. This results in an IC50, half maximal inhibitory concentration, 
score for a given peptide and its cognate MHC I. It is important to note that this technique does 
9 
 
not account for the highly complex peptide loading pathway that has been observed in vivo
22
, 
which could aid in the loading of less stable peptides
33
. It has been demonstrated that the peptide 
loading complex, most importantly tapasin, plays a crucial role in the loading of endogenous 
peptide, where in vitro studies would consider that peptide unable to bind MHC I
34
. With current 
methodologies unable to recapitulate the peptide loading complex in vitro, measuring whether or 
not a peptide will bind to MHC I is limited to the measurement of the IC50 for a given peptide. 
Furthermore, these in vitro measured IC50 concentrations, from known viral and model antigens, 
are used to train current binding affinity predictions algorithms used today.    
 
There are currently more than a dozen various prediction algorithms for predicting the binding 
affinity of peptides, with NetMHC
35
 being the most widely used and validated algorithm for 
neoepitope prediction pipelines. Like most prediction algorithms, NetMHC has been trained with 
an artificial neural network (ANN), and outputs a predicted IC50. With over 11,000 variants at 
the human class I loci identified, according to the IMGT/HLA database
36
,  and the less common 
HLA’s peptide binding kinetics being poorly studied, accurately predicting a peptides ability to 
bind to its cognate MHC I has been very difficult in itself. For the more commonly studied MHC 
I molecules, standard criteria have been established to predict the likely immunogenic peptides 
that can be applied to all HLAs as more are characterized. 
 
The thresholds used today to determine which peptides are most likely to elicit a cytotoxic T 
lymphocyte (CTL) response were established over two decades ago, and set the standard that an 
IC50  500 nM, preferably 50 nM or less, is considered a strong to intermediate binder and 
determines an epitope’s capacity to elicit a CTL response37. This criterion has been highly 
10 
 
validated in viral and model antigen systems where there is no “self” counterpart. Since 
neoepitopes arise from altered self-peptides, neoepitope specific T cells potentially face thymic 
deletion and tolerization. This issue was addressed by Duan et al., where they tested the 
differential agretopicity index (DAI) score, that compares the binding affinity of the mutated 
peptide to the reference peptide
38
. This score indirectly accounts for how different the peptide is 
from “self”. In that study, they identified three neoepitopes that were able to effectively inhibit 
tumor growth in two different BALB/c tumor models, yet had IC50 scores significantly above the 
500 nM threshold. By current standards, these neoepitopes would have been overlooked and not 
considered immunogenic based of their binding affinity alone.  
 
On the contrary, studies by Gubin et al.
39
 and Yadav et al.
40
 have each identified neoepitopes 
that fit the strong affinity criterion that were able to effectively target the tumor. It is worth 
noting that work done by Assarsson et al.
41
 in a viral model system established that about 7.5% 
of the predicted high affinity binders are actually recognized by the immune system, yet in the 
tumor model system the frequency of validated high affinity binders to those predicted to be 
immunogenic is significantly lower. This observation is supported by the work of Van Rooij et 
al. that reported that less than 1% of the high affinity binders predicted from a melanoma patient 
were able to be recognized by the patient’s T cells42. 
 
Surprisingly, it was recently found that proteasome-generated spliced epitopes account for one 
fourth of the HLA class I immunopeptidome in terms of abundance
43
. This accounts for a large 
repertoire of proteasomal spliced peptides and current prediction methods do not take these 
peptides into consideration, as criteria for what peptides get spliced has not been established. 
11 
 
Moreover, the importance of post-translationally modified proteome substrates is of importance 
and currently overlooked. It has been clearly demonstrated that post translational modifications, 
such as phosphorylation, methylation, and glycosylation, can be recognized by the immune 
system as foreign compared to their unmodified counterpart
44
. With the advancement of mass 
spectrometry, it is now possible to identify these non-canonical antigens and develop programs 
that consider these modifications. 
 
The dependence on using binding affinity as a major predictor of putative neoepitopes, while 
useful in some cases, may be limiting our ability to accurately identify all neoepitopes. The 
criteria of what makes a good neoepitope have yet to be established, but with the identification of 
more neoepitopes and consideration of weak affinity and non-canonical neoepitopes, we can start 
to identify and set the criteria that can help more accurately predict neoepitopes. Only then will 
we further understand what makes a good neoepitope.  
 
How should we immunize against neoepitopes? 
Since neo-antigens are small pieces of peptides harboring tumor mutations, immunization with 
them usually needs strong immunostimulatory agents to produce efficient immune response. 
Peptides as vaccines may not be able to stimulate the immune system powerfully enough on their 
own. Therefore, it is usually required to use an adjuvant in combination in order to elicit an 
effective immune response 
45
. The word adjuvant comes from the Latin word adjuvare that 
means to enhance or help. The role of adjuvant is to enhance the immune system against the 
antigen which is co-inoculated
46
.  
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In order to activate naïve cytotoxic T cells and have a robust immune response, usually 
stimulation of T helper (Th) cells is needed
47
. Synthetic peptides designed to stimulate cell 
mediated immunity often do not have a proper Th-epitope and therefore they are not efficient by 
themselves
48
. Even with the proper T cytotoxic and Th cell epitopes, an adjuvant is still required 
in order to have an effective peptide based vaccine
49
. Based on our laboratory’s unpublished data 
on BALB/c mice, using a potent immunostimulatory adjuvant and delivery system for neo-
epitope immunization seems crucial to have an effective tumor rejection response.  
 
In order to get a maximized cytotoxic T lymphocyte response in cancer immunotherapy, besides 
proper neoepitope, appropriate adjuvant that can induce production of cytokines and co-
stimulatory molecules from APCs is required. It is also important that the adjuvant delivers 
optimum amount of the antigen by controlling antigen persistence and concentration
50
. There 
should be a balance between antigen persistence and delivery. Long term antigen persistence at 
the site of injection may have adverse results in tumor rejection and cause CD8 T cell 
dysfunction and deletion
51
. Adjuvants function in different ways including releasing the antigen 
gradually
52,53
, stimulating pattern recognition receptors on APCs
54,55
, and protection of antigens 
from rapid degradation and therefore extending the antigen presentation time
56,57
.  
 
Different types of adjuvants have been tested in cancer therapy vaccines such as mineral 
adjuvants and cytokines
58
, RNA based adjuvants
59
, liposomes
60
, tensoactive agents
61
, and 
bacterial products
62
. In some studies, different types of cells were pulsed with neoepitopes for 
immunization. These cells including B cells
63
, macrophages
64
, splenocytes
38
 and dendritic cells
65
 
serve as both delivery system and adjuvant. 
13 
 
 
Dendritic cells (DC) as professional antigen presenting cells play a major role in initiating 
immune response
66
. Since the early clinical trials testing effectiveness of DC vaccines in 
cancer,
63,67
 it wasn’t until 2010 that the first cancer antigen presenting cells/DC-based vaccine 
(Sipuleucel-T) got FDA approval
68
. Since DCs are able to efficiently uptake, process and present 
the antigen and initiate the immune response, they may be considered as natural adjuvants
69,70
. 
Although there are many studies using dendritic cells as delivery system for different cancer 
immunotherapies  that are showing promising results on T cytotoxic cell response,
71–73
 most of 
them failed to induce good tumor rejection
74,75,76,77
. One of the challenges in using DCs as 
delivery system in neoepitope cancer therapy is providing enough functional DCs for each 
patient that may not be achieved by isolating patient blood DCs
78
. The number of blood DCs in 
cancer patients often is reduced
79
 and they may be functionally impaired due to tumor 
microenvironment systemic effect
80
. There are other ways to get syngeneic DCs including in-
vitro differentiation of blood monocytes
81
, hematopoietic stem cells
82
 or bone marrow derived 
stem cells
83
, in which each have their own hurdles. Different variables using DCs play a major 
role in the final anti-tumor immunity caused by dendritic cell neoepitope based cancer vaccine; 
such as DC maturation status
84,72
, DC type, number of the injected DCs and injection location
85
. 
It is clear that having the appropriate tumor neoepitope is one of the most important elements in 
cancer immunotherapy by DCs. However, determining the exact DC subtype that works the best 
as adjuvant for immunotherapy may be one of the future directions in DC based vaccines.  
 
Combinatorial Therapies 
14 
 
It is now beyond doubt that the immune system, and more specifically, the T cell compartment 
have the ability to control and eliminate tumor lesions.  Neoepitopes sit at the forefront of cancer 
immunotherapy, in that they are the prospective means by which the immune system can 
distinguish normal self from mutated self and selectively eliminate only cancerous cells
86,87
.  
Further, many immunotherapies, traditional cancer treatment modalities (such as chemotherapy 
and radiation) and disease progression all potentially affect responses to neoepitopes either 
directly or indirectly
88,89
. However, even armed with the knowledge of neoepitopes and 
improved techniques and tools for identifying and targeting them in vivo, no “silver bullet” 
treatment has emerged for treating all cancers.  
 
As discussed in the preceding sections, myriad advances have been made in the last few years 
with regards to the identification, importance and utility of neoepitopes.  However, there remain 
significant hurdles in leveraging this information into effective treatment modalities.  A 
particular challenge is with the treatment of solid tumors.  While other related immunotherapies, 
such as chimeric antigen receptor (CAR) T cells, have shown considerable improvements in 
outcomes for many liquid or blood tumors, solid tumors have been more difficult to target with 
this approach
90
 given that most solid tumors lack the well characterized surface markers found 
on blood cell subtypes.  Further, factors within the tumor microenvironment (TME) can work in 
concert to create an immunosuppressive milieu that can limit the local effectiveness of a strong, 
systemic anti-tumor immune response
91
.  TME elements such as suppressor cell types 
(Regulatory T Cells, Myeloid Derived Suppressor Cells, etc.), suppressive cytokines, 
extracellular matrix and vasculature remodeling, T cell exclusion, and others are all means by 
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which cancer cells can alter their environment and coopt the host immune system for their 
protection.   
 
Specific therapies, such as immune checkpoint blockade, have been developed to target 
immunosuppressive components.  The idea behind these treatments is that by targeting the co-
inhibitory molecules CTLA-4 and PD-1 found on T cells, the inhibitory signaling or “brakes” 
can be removed from these cells thus generating a stronger anti-tumor response
92,93
. These 
therapies have generated exciting and durable responses for many different types of cancer
94–98
.  
However, these responses remain limited to only a subset of patients, which can differ 
significantly between tumor types.  Determining biomarkers that can identify which subset of 
patients respond to treatment has become critical for both improving treatment outcomes and 
understanding their actions mechanistically.  To this end, studies examining anti-CLTA-4 
antibody therapy have demonstrated that its efficacy may be a result of depleting Regulatory T 
cells from the TME and not simply taking the “brakes” off of effector T cells99–101. The lack of a 
universally effective treatment method owes in part to the complexity of the tumor and its 
microenvironment. This complexity has been demonstrated not only in the significant disparities 
between different tumor types but further as the vast heterogeneity within a single patient’s 
lesion(s)
89
.  Numerous factors such as differences in tumor cell clonality, immune cell 
infiltration, angiogenic factors, mutational burden, etc. contribute to treatment response and 
ultimately determine treatment outcomes. 
 
It is becoming increasingly evident that while individual immunotherapeutic regimes have 
exciting potential, it will likely take a combinatorial, and more importantly, patient specific 
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approach to achieve optimal treatment outcomes on a patient-by-patient basis
102
.  To this end, 
trials examining the combination of checkpoint inhibition therapies using antibodies targeting 
CTLA-4 and PD-1/PD-L1 have shown synergistic improvements for some patients
103
.  Yet, 
considerable side effects of such combinatorial treatments remain a challenge.  The development 
of other therapies that target additional co-inhibitory or co-stimulatory molecules is also 
underway.   Other T cell surface molecules such as the co-inhibitory markers LAG-3 and TIM-3 
and the costimulatory receptors OX40, GITR, and 4-1BB are currently under evaluation 
individually and in combination with other checkpoint based therapies for their utility as anti-
cancer agents
104
.  Given the specific TME milieu for each individual tumor, precise checkpoint 
targeting may improve outcomes for certain subsets of patients. 
 
Even as other immunotherapies become more “patient specific”, neoepitopes endure as the most 
targeted approach to cancer treatment.  The identification of patient specific neoantigens allows 
for a directed immune response to tumor specific epitopes.  There are many different approaches 
examining how best to elicit a strong, specific and long-lasting neoepitope immune response.  
One set of methodologies revolves around a vaccine-based approach.  As previously described in 
this review, a host of different vaccination strategies from synthesized peptides to whole cell or 
cell lysate products in a mixture with adjuvant can be used as cancer targeted vaccines.  Other ex 
vivo based methods such adoptive cell transfer (ACT) or CAR–T cell aim to selectively expand 
or engineer T cells with specificity to neoepitopes and re-infuse these cell products back into the 
patient.  The overarching goal of neoepitope therapies is to effectively “educate” the immune 
system to the best tumor specific targets while eliciting a strong T cell based response that can 
hopefully overwhelmed a tumor’s defense mechanisms and elicit complete tumor rejection12. 
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The future of neoepitope based cancer immunotherapies 
It is evident that all the components of a neoepitope-based therapy, from their in silico 
identification to optimal immune system activation, are critical to realizing their therapeutic 
potential.  While neoepitope targeted approaches have moved from the laboratory to the clinical 
setting, outcomes have remained varied and suboptimal.  Much in the same way as other 
immunotherapies demonstrate durable responses for only a subset of patients, utility of 
neoepitope focused strategies are likely dependent on the context of the tumor and the TME.  As 
more information continues to clarify our understanding of the interrelated cancer immunology 
mechanisms such as TME associated suppression, T cell exclusion, T cell exhaustion, immune 
checkpoint regulation, tumor heterogeneity, etc. it is becoming clear that no single targeted 
approach will be sufficient to treat the vast majority of cancers.  Moving forward, optimal 
therapeutic advances will likely need to include multiple immune directed treatments that are 
tailored not only to the patient’s specific neoepitope repertoire but also to the unique suppressive 
landscape of the individual TME.   
  
For my thesis, I set aside all preconceived notions of what makes a good neoepitope. Instead of 
predicting what neoepitopes to use in a vaccine, I tested every somatic mutation’s epitope for its 
ability protect a host from tumor challenge. In doing so, I identified the best candidate 
neoepitopes for a given murine tumor cell line, and have begun to understand the criteria that 
make for a strong candidate neoepitope. Through this exhaustive and exhausting study I have 
made substantial discoveries, and identified many more scientific questions that need to be 
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investigated further before neoepitopes become a major contender in personalized cancer 
immunotherapies.  
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Chapter 2 
 
 
Materials and Methods  
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Location of research facilities 
All experimental procedures on live animals were performed in B1005A (Procedure Room) in 
the animal facility at UConn Health, Farmington. All experiments not involving live animals 
were performed in Dr. Pramod K. Srivastava’s laboratory (Room L1008). Accordingly, all the 
apparatus and reagents required for the experiments were provided by Dr. Srivastava. Flow 
cytometry was performed either in Dr. Srivastava’s laboratory or at the flow cytometry core 
facility located in room E6014 at UConn Health. FlowJo, a software to analyze the data recorded 
using flow cytometers, was made available by Dr. Srivastava’s laboratory. Experiments 
measuring the binding affinities of synthetic peptides to MHC class I molecules were performed 
by Dr. John Sidney in the laboratory of Dr. Alessandro Sette at La Jolla Institute for Allergy and 
Immunology in San Diego, CA. Experiments using molecular modeling were performed by Dr. 
Brian Baker at the University of Notre Dame in Notre Dame, IN.  
 
Vertebrate Animals 
In this study, 6-8 week old female C57BL/6 mice from Jackson Laboratories™ were used. Mice 
were housed and cared for by the Center for Comparative Medicine at the University of 
Connecticut Health, and all procedures can be found in the approved Srivastava protocols, 
reference number 101350-0619. 
MC38-FABF cell line 
A chemically induced murine tumor cell line in the C57BL/6J background known as MC38-
FABF was used as the primary tumor model for this extensive study. MC38-FABF tumor cell 
line was graciously provided by Dr. Alan B. Frey at NYU Langone Health. 
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Sequencing 
Sequencing of cDNA was performed by the Illumina NextSeq 500 Sequencing System. 
Sequencing was performed following the EpiSeq pipeline as previously described by Duan et 
al
38
. SNVs were called using normal mouse reference sequences. Whole exome sequencing was 
followed by transcriptome sequencing to call expressed SNVs with the least incidences of false 
positives. Further, to validate these SNVs, Sanger sequencing was performed for all SNVs. 
 
Culture Complete Media 
All cells were cultured in RPMI that are supplemented with 10% FBS, 1% 
penicillinstreptomycin-glutamine, 1% MEM, lx beta-mercaptoethanol, and 1% sodium pyruvate.  
 
Generation of BMDCs 
BMDCs were generated as per Inaba et al
105
. Bone marrow from femurs and tibias of ∼6-8 week 
old mice were cultured with 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-
CSF) in complete RPMI media for 7 days at 37˚C and 5% CO2.  
 
Peptides 
The peptides used in this thesis were ordered from JPT in Berlin, Germany. They were 
synthesized with a purity of  >90%. The peptides were dissolved in DMSO at a final 
concentration of 20 mM and stored at -20˚C. 
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Immunizations 
BMDCs, ~7x10
6
 cells, were pulsed with 100µM of peptide in RPMI complete media for ~1 hour 
at 37˚C and 5% CO2.. They were washed once in RPMI only. Mice were immunized twice, a 
week apart with ~6 million pulsed BMDCs intradermal in the belly.  
Tumor challenge and representation of tumor growth. 
Mice were challenged with 30,000 tumor cells intradermally in the right rear flank. Tumor 
volumes were measured every 3 days post tumor challenge using the Biopticon TumorImager™. 
Mice were euthanized when tumors reached a volume of 2000mm
3
. Tumor Control Index scores 
were calculated for every experiment as described by Corwin et al
106
. 
 
Tumor sample preparation 
Tumors were harvested on day 25 post tumor challenge. Tumors were dissociated using 
Miltenyi™ Tumor Dissociation Kit, mouse. CD8+ TIL were isolated with STEMCELL’s 
EasySep™ murine CD8 negative selection kit. 
Intracellular IFNγ assay by ELISpot. 
CD8
+
 cells were isolated from spleens of mice immunized with neoepitopes using the magnetic 
bead isolation (Miltenyi Biotec™). Negative controls were CD8+ cells from immunized mice 
without peptide stimulation. IFNγ ELISpot reagents were obtained from MABTECH™. As 
targets to stimulate the CD8
+
 cells, naive splenocytes pulsed with peptide were added to the 
wells. Plates were analyzed by ZellNet™. Peptides were considered to have a positive CD8 
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response when spots from peptide-stimulated wells were significantly higher than that without 
cognate peptide stimulation.  
Depletion of T cell subsets. 
CD8
+
 cells were depleted in immunized mice using anti-CD8 rat IgG2b monoclonal antibody 
2.43 (Bioxcell™). CD4 cells were depleted using anti-CD4 rat IgG2b monoclonal antibody 
GK1.5 (Bioxcell™). Isotype control groups were given anti-LTF2 rat IgG2b monoclonal 
antibody (Bioxcell™). Depleting antibodies were given in PBS i.p. 2 days before each 
immunization and every 7 days for the duration of the experiment. The first 2 injections of 
depleting antibodies given before each immunization were 250 µg per mouse; later injections 
were 100 µg per mouse. The antagonistic antibody, anti-CTLA-4 (clone 9D9; Bioxcell) was 
given at 75 µg, 7 days before and every 3 d after tumor challenge. The appropriate T cell subsets 
were depleted by >95%. 
Flow Cytometry 
The plasticity flow panel was graciously provided by Dr. Andrea Schietinger at MSKCC. The 
antibodies for CD8α PacificBlue (clone 53-6.7), CD38 APC (clone 90), Lag3 (clone 
eBioC9B7W), PD-1 PCP-Cy5.5 (Clone RMP1-30), Tim3 APC (Clone RMT3-23), and CD62L 
APC-Cy7 (Clone MEL-14) were purchased from Biolegend™. The antibody for 2B4 PE-Cy7 
(Clone eBio244F4) was purchased from ThermoFisher™. The antibody for TCF1 Alexa Flour 
488 (Clone C63D9) was purchased from Cell Signaling™.  Ab Flow cytometry was performed 
using Miltenyi Biotec MACSQuant analyzer. Analysis was done using FlowJo software (FlowJo 
LLC). 
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Molecular Modeling 
Modeling was performed by Grant Keller in the lab of Dr. Brian Baker at the University of Notre 
Dame. Molecular modeling was performed for the precise neoepitopes that showed a significant 
tumor response. Low-resolution centroid modeling was followed by high-resolution refinement 
and then repeated 10,000 times to find the highest likely conformation of the neoepitope and its 
wild type counterpart. PCA analysis was conducted on density-based spatial clustering of 
applications with noise (DBSCAN) to find the modeled populations with the favorable lowest 
energetic scores. Differences were also quantified by superimposing average peptide 
conformations from the molecular dynamics simulations and computing RMSDs for all common 
atoms. Cox6a2 was modeled for H-2K
b
 and Fam171b was modeled for H-2D
b
. 
 
Statistical analysis 
P-values for group comparisons were calculated using a two-tailed nonparametric Mann–
Whitney test, using GraphPad Prism 5.0 (GraphPad). Fisher’s exact test was used to test 
association between pairs of categorical parameters. Statistical significance of a Pearson 
correlation coefficient was computed using two-sided Student’s t test as described in Cohen et 
al
107
. Statistical analysis on percent survival curves was conducted using the log rank (Mantel-
Coz) test. 
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Chapter 3 
 
 
Identification and characterization of tumor 
protective neoepitopes  
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Introduction 
 
It is evident that using the binding affinity of a neoepitope to its cognate MHC may be a limiting 
factor in designing a tumor rejecting vaccine. With less than 1% of predicted high affinity 
antigens eliciting a tumor specific immune response, the odds of accurately selecting the true and 
effective neoepitopes for vaccination are very low
42
. It is even more difficult to accurately 
predict multiple neoepitopes that can account for the heterogeneity of a tumor that may only 
contain one of the targets at a time. Evidence of this can be seen in patients treated with various 
cancer immunotherapies and the tumors escape with neoantigen loss
108–110
. Until this study, all 
neoepitopes in a murine model system have been identified using binding affinity as a criterion 
and only identified a few neoepitopes, as shown in Table 2. The study, by Duan et al, was able to 
predict the most neoepitopes for a tumor cell line that were capable of rejecting tumor growth
38
. 
Using DAI as a prediction criterion may be the most accurate and is also consistent with a large 
amount of clinical data in patients that received checkpoint blockade
111,112
; however this 
algorithm still needs to be improved upon. 
 
According to the NIH U.S. National Library of Medicine Clinical Trials there are more than 80 
clinical studies either testing or looking at the neoepitopes in various cancer types
113
. As more 
data evolves, we will further begin to understand the efficacy of various neoantigen selection 
strategies. Some early studies solely identified the presence of neoepitope specific CD8
+
 and 
CD4
+
 TILs of melanoma patients that had responded to checkpoint blockade
114–118
. The first 
completed human vaccine Phase I trials in advanced melanoma patients tested the safety and 
efficacy of neoepitope vaccines using neoantigen pulsed DCs, synthetic long peptide (SLP) and 
polyepitope mRNA neoantigen vaccines.  
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This table lists the important genetically identified neoepitope papers that have set the foundation for all human 
clinical neoepitope studies, and lists how many neoepitopes were tested and successful at rejecting tumors. 
Table 2 | Genomically defined murine neoepitope studies   
Paper No. of models tested for 
tumor rejection 
No. of neoepitopes tested 
for tumor rejection 
No. of neoepitopes found 
positive for tumor rejection 
Brennick, George, Srivastava 
(Unpublished) 
1 (MC38-FABF) 279 (within groups) 
120 (as individuals) 
9 
Ebrahimi-Nik, Srivastava 
(Unpublished) 
1 (MethA) Long peptide- 7 
Precise peptide- 11 
Long peptide- 4 
Precise peptide- 5 
Yadav, Nature, 201440 2 (MC-38, TRAMP-C1) MC-38- 3 
TRAMP-C1- 0 
MC-38- 3 
TRAMP-C1- 0 
Gubin, Nature, 201439 2 (d42m1-T3, F244) d42m1-T3- 2 d42m1-T3- 2 
28 
 
  
Duan, J.Ex. Med, 201438 2 (MethA, CMS5) High affinity 
MethA-11 
CMS5- 7 
DAI 
MethA- 28 
CMS5- 20 
High affinity 
MethA-0 
CMS5- 0 
DAI 
MethA- 4 
CMS5- 6 
Castle, Cancer research, 2012119 1 (B16F10 melanoma) 2  2 
Kreiter, Nature, 2015120 3 (B16F10, CT26, 4T1) B16- 1 
CT26-10 
B16-1 
CT-26- 5 
This table lists the important neoepitope papers that have set the foundation for all human clinical neoepitope 
studies, and list how many neoepitopes were tested and successful at rejecting tumors.  
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The first trial by Carreno et al, looked for neoepitope specific T cell responses in patients 
immunized with DCs pulsed with seven of the highest predicted binding affinities to the patients 
HLAs
121
. They demonstrated that they were able to successfully expand pre-existing neoepitope 
specific T cells and identify new TCR clones not seen before treatment. However, this study did 
not report the tumor responses of these patients. The other two studies by Ott et al and Sahin et al 
that used similar binding affinity prediction algorithms, did report the patient outcomes
122,123
. In 
the study by Ott et al, they vaccinated patients with SLPs post-surgical resection and looked 
primarily at T cell responses to the immunized peptides. Although the peptides were selected for 
electing CD8
+
 responses, the overwhelming responses observed were CD4
+
 T cells. Even though 
clinical observations were reported, the number of patients tested in both studies (six in Ott et al 
and thirteen in Sahin et al) was too small to obtain any information about vaccine dependent 
clinical activity. Interestingly, roughly 20% of the measurable T cell responses by Sahin et al 
were predicted to have a poor binding affinity to HLA class I and II. By solely using binding 
affinity criteria alone, these neoantigens would have been overlooked in any other study. 
However, the measured binding affinities of these neoantigens were not measured, therefore it is 
not known if they are truly weak binders or the predicting algorithms are not accurate.  
 
In this thesis, I did not use binding affinity as a criterion to identify putative neoepitopes. I have 
used exome and RNA sequencing to identify all expressed somatic mutations, design 21mer 
SLPs, and tested them for tumor rejection capabilities in a C56BL/6 model. This allowed us to 
identify all neoepitopes for a single cancer cell line, and I was then able to begin to dissect what 
makes them strong neoepitopes. Since previous studies have debated the importance of CD4
+
 
and CD8
+
 T cells in tumor rejection and specifically orchestrating bystander killing
124
, I 
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determined the specificity of the neoepitopes. Furthermore, I tested the necessity of having 
multiple neoepitope targets to overcome antigen escape. 
 
This study will not only identify neoantigens, but will aim to shed light on what factors 
contribute a neoepitope specific tumor rejection. It will generate vast amounts of data that can be 
used later on to extensively identify the criteria that are necessary for selecting the strongest 
candidate neoepitopes. It is only once we truly understand what makes a good neoepitope that 
personalized neoepitope vaccines will be an effective treatment modality. 
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Results 
 
 
Identification of SNVs in MC38-FABF tumor cell line 
A chemically induced murine colon cancer cell line in the C57BL/6J background, known as 
MC38-MC38-FABF, was used as the primary tumor model for this extensive study. This cell 
line develops an aggressive tumor and does not response to checkpoint blockade on its own. In 
order to identify all possible SNVs expressed by MC38-FABF, the EpiSeq pipeline as previously 
described by Duan et al
38
 was used. SNVs were called using normal mouse reference sequences. 
Whole exome sequencing was followed by transcriptome sequencing to call expressed SNVs 
with the least incidences of false positives. Exome sequencing revealed 1883 SNVs and 
transcriptome sequencing brought the number of expressed SNVs down to 328. Further, to 
validate these SNVs, sanger sequencing was performed for all SNVs called. This again reduced 
the number of expressed SNVs to 279 (Figure 2). For these candidate neoepitopes, 21 amino acid 
long peptides were generated, with the mutation at the center of the peptide. This is to take into 
consideration all putative 8-11mers that can be presented by the major histocompatibility 
complex (MHC) class I. 
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Figure 2 | Pipeline for epitope calling 
Represented is a broad overview of the sequencing pipeline for calling somatic mutations of the MC38-FABF cell line. 
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Predicted neoepitopes are capable of eliciting tumor protection  
MC38-FABF is capable of inducing progressively growing tumors, which is lethal in an 
untreated syngeneic host. Furthermore, MC38-FABF is immunogenic as it is capable of eliciting 
protection against subsequent tumor challenge upon immunization with irradiated tumor cells 
prior to challenge (Figures 3a-c). In order to test that the tumor protection is neoepitope specific, 
mice were immunized with a cocktail of all 279 synthetic peptides (Figure 3d). This strategy 
resulted in reduced tumor growth, but did not result in complete protection like the irradiated 
tumor when tested as a vaccine. The irradiated cells themselves may contain other factors that 
are responsible for the complete protection, which needs to be investigated further. Since the 279 
peptide vaccine showed significant tumor control over the BMDCs alone group, I next wanted to 
further identify the SNVs that are responsible for this observed response.  
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Figure 3| MC38-FABF immunizes against itself and has tumor protective epitopes 
a-b. MC38-FABF intradermal injections induce tumors in C57BL/6 mice that have not received any vaccination (naïve) or 
BMDC control. b. Mice immunized with irradiated MC38-FABF cells elicit complete protection from tumor challenge. c. 
Mice were vaccinated with BMDCs pulsed with all 279 peptides and tumor growth curves are shown; (a-c) n=5 mice/group 
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Screening of all potential neoepitopes  
The 279 peptides were randomly grouped into pools of five peptides per group and tested for 
tumor rejection following prophylactic immunization. Since these were long peptides that 
required processing for MHC class I presentation, bone marrow derived dendritic cells (BMDCs) 
were used as a neoepitope delivery system. Studies from our lab have shown that BMDCs 
outperform other neoepitope delivery systems
125
. Further, to prevent discrepancies in peptide 
uptake due to competition, BMDCs were separately pulsed with each individual neoepitope from 
the group. The individually pulsed BMDCs were then pooled together and used to immunize 
mice via the intradermal route followed by tumor challenge with live tumor cells. The 
immunization protocol has been previously described and illustrated along with the screening 
plan in Figure 4. Tumor control index (TCI) scores as described by Corwin et al
106
, were 
calculated for all 56 groups tested and normalized to the control group (BMDC only) as shown in 
Figure 5. 
 
Of the groups tested, just over 42% (24/56 groups) had a positive score, with only two groups 
showing significant tumor control (Figure 5a). The 120 peptides within these groups were 
selected for further testing for their capacity to elicit a tumor response as an individual peptide 
immunization. TCI scores for the individual neoepitopes were calculated as shown in Figure 5b. 
Of the 120 peptides tested, 50% (60 peptides) showed a positive TCI score. Only 7.5% (9 
peptides) of all the individual peptides tested showed significant tumor control when compared 
the control groups. 
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Figure 4 | Peptide screening strategy 
Represented is the experimental scheme for rapidly and efficiently screening all 279 peptides for their ability to elicit tumor 
rejection. 
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Figure 5| Positive tumor control index (TCI) scores of grouped peptides and the individual peptides of those groups 
These figures represent data from peptides which eleicited a positive tumor control index (TCI) scores. a. The x-axis 
corresponds to the group number label of 5 peptides tested. TCI scores were calculated for each group, and compared to the 
BMDC control group for significance; n=5 mice/group. b. Individual peptides tested from groups with a positive TCI 
score. The x-axis corresponds to the peptide number tested. TCI scores were calculated for each group, and compared to 
the BMDC control group for significance as described by Corwin et al98; n=10 mice/group (a-b) Means ± s.d.  shown.; red 
*p<0.05 (Student’s t- test). 
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Multiple neoepitopes shows additive effect in tumor control 
I made the observation that the top performing grouped vaccines in the initial screening (Figure 
5a) did not result in individual neoepitopes that were able to elicit significant tumor control. For 
example, the top performing group 37 showed significant tumor control as a group, but when 
tested as individual neoepitope vaccines did not show any significant control. Interestingly, when 
taking the sum of the TCI scores for the individual peptide vaccines, they almost exactly add up 
to the group score. This may suggest that neoepitopes are additive in their effectiveness, and 
multiple targets may be necessary for an effective treatment modality.  
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Figure 6 | Multiple targets show additive effect in tumor control 
a. The table contains TCI scores for each of the individual peptides tested in Group 37. The sum of the scores are nearly identical to 
the TCI score of all the peptides as a grouped vaccine. b. The average tumor growth curves for Group 37 vaccination; *p<0.05 
(Student’s t-test) c. The average tumor growth curves for every individual peptide in Group 37. Means ± s.e.m.  shown. (a.b.) n=5 
mice/group 
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In order to test this hypothesis, I combined all 279 peptides into a single vaccine and only the top 
nine significant neoepitopes into another vaccine and tested the tumor growth responses. The 
combination of the top nine neoepitopes outperformed all vaccines tested to date (Figures 7a-b), 
confirming that multiple targets have a stronger effect than a single neoepitope. In addition, 
having selected only identified effective and relevant neoepitopes rather than all SNVs, 
regardless of performance, increased the vaccine efficacy.    
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Figure 7 | Combining neoepitopes elicit the strongest tumor response 
a. Combining all 279 peptides into one vaccine show slowed tumor growth, although not to a 
statistically significant degree.  Combining only the top 9 neoepitopes showed significantly slowed 
tumor growth over the controls, and is the best performing vaccine in this study to date. Means ± s.e.m. 
shown. b. TCI scores are represented for the top 9 peptides as individual vaccines, all 279 peptides in 
one, or the top 9 in one vaccine. Means ± s.d. shown. (a.b.) n= 10; p<0.05 (Student’s t-test). 
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Detectable tumor specific CD8
+
 T cell response does not always result in tumor protection  
Since we know that MC38-FABF immunized mice elicit complete protection to subsequent 
tumor challenge, I wanted to test which neoepitopes are recognized by these mice. Mice were 
immunized twice with irradiated MC38-FABF tumor cells, and then CD8
+
 enriched cells from 
the spleens of these mice were tested for their recalled IFNγ response to all 279 peptides pulsed 
onto splenocytes via ELISpot. Of the 279 peptides tested only 30% (84/279) showed any positive 
T cell response with 9.4% (26 peptides) showing a significant response (Figure 8). Within the 
nine peptides that showed significant tumor response in the previous tumor rejection screening, 
only two peptides were observed to have a significant CD8
+
 response against MC38-FABF 
immunized mice.  
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Figure 8 | Top 50 CD8+IFNγ+ responses against peptides of mice immunized with irradiated tumor MC38-FABF 
a. Experimental scheme. b. This data shows to top 50 immunogenic peptides that recalled responses against MC38-FABF 
immunized mice. Splenocytes pulsed with each of the 279 peptides were used as targets. Each grey and overlaying black 
bar represents the response against MC38-FABF immunized mice and naïve mice respectively (n=4). Statistical analysis 
was conduct for each peptide response against wells with no target. Means ± s.d. shown; *p<0.05 (Student’s t-test); 
#(red) peptide elicited significant tumor control.   
 
44 
 
 
Weak binding affinity neoepitopes outperform high affinity neoepitopes in tumor rejection 
After extensive testing of all the individual peptides within groups with a positive TCI score, I 
found nine peptides that caused significant tumor control (Table 3).  Only a single peptide was 
within the top 10% of predicted binding affinities for both H-2K
b
 and H-2D
b
. Of the neoepitopes 
that had a significant tumor response, only two are predicted to bind MHC class I. Furthermore, 
the highest tumor control scoring neoepitopes have a predicted binding affinity well above the 
minimum 500 nM threshold
37
. This data suggests that binding affinity alone is not a predictor of 
a strong tumor response and through only screening putative neoepitopes below the 500 nM 
threshold, the best candidate neoepitopes for tumor rejection would be overlooked.  
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Table 3 | Top nine neoepitopes’ predicted binding affinities 
Table shows specifics about each of the top nine working peptides. IC
50
 scores (nM) for H-2K
b
 and H-2D
b
 are predicted 
using the NetMHC4.0 algorithm. DAI scores are calculated as per Duan et al. Peptides highlighted in red elicited a 
significant IFNγ response in MC38-FABF immunized mice.  
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The strongest candidate neoepitopes Cox6a2 and Fam171b 
The top two neoepitopes that have consistently showed the strongest activity in terms of tumor 
regression are namely 261 and 209, now referred to by their gene names, Cox6a2 and Fam171b 
respectively. (Figure 9a). In addition overall tumor growth control, the survival of mice 
immunized with either neoepitope was significantly longer compared to control mice (Figure 
9b). Wild type counterparts of Cox6a2 and Fam171b do not elicit any tumor protective 
confirming the specificity of these neoepitopes (Figure 9c). In order to test previous observations 
that neoepitope tumor control is additive, I tested the combination of both Cox6a2 and Fam171b. 
In concurrence with earlier observations, the combination of Cox6a2 and Fam171b overall 
performed better than as individuals (Figures 10b-c).  
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Figure 9| The strongest candidate neoepitopes Cox6a2 and Fam171b 
a. The average tumor growth curves for BDMCs only compared to peptide 261 or 209. Means ± s.e.m. shown. b. Percent 
survival curves for BDMCs only compared to peptide 261 or 209. Statistical analysis was performed using the log rank 
(Mantel-Coz) test. (a.b.) n=15 mice/group c. The average tumor growth curves for BDMCs only compared to the mutant or 
wild type peptides of 261 or 209. Means ± s.e.m. shown; n=5 mice/group. (a.c) *p<0.05 (Student’s t-test) 
 
48 
 
Until now, all neoepitopes were tested in a prophylactic model. I next wanted to test these 
neoepitopes in a therapeutic model, where vaccination does not occur until tumor challenge 
(Figure 10a). Both Cox6a2 and Fam171b showed significant tumor control in a therapeutic 
model, with Cox6a2 showing significant increase in survival. As observed previously, the 
neoepitopes performed best in combination for therapy, confirming that a combination of 
neoepitopes works best (Figures 10d-e).  
 
  
Figure 10 | Cox6a2 and Fam171b show significant tumor control in both prophylactic and therapeutic models 
a. Experimental scheme: In the prophylactic model mice were immunized twice prior to tumor challenge. In the therapeutic model 
mice the vaccine was administer the same day as tumor challenge and were given boost one week later. b,d. The average tumor 
growth curves for BDMCs only compared to peptide(s) 261, 209 or the combination of 261 and 209. Means ± s.e.m. shown. c,e. 
Percent survival curves for BDMCs only compared to peptide(s) 261, 209, or the combination of 261 and 209. Statistical analysis 
was preformed using the log rank (Mantel-Coz) test. (b-e) n=10 mice/group (b,d) *p<0.05 (Student’s t-test) 
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Anti-tumor activity of the best neoepitopes is CD8 dependent  
Through using 21 amino acid long peptides for immunization, it is possible to stimulate both 
CD8 and CD4 T cell responses. It was unclear whether Cox6a2 and Fam171b neoepitopes were 
CD8 dependent, since no significant CD8
+
IFNγ response was measureable against MC38-FABF 
immunized mice. To test whether the tumor immunity of our top neoepitopes are CD8 or CD4 
dependent, mice were depleted of CD8
+
 or CD4
+
 cells through antibody depletion prior to 
immunizations and continued post tumor challenge (Figure 11a). Cox6a2 and Fam171b 
immunity was significantly lost when mice were depleted of CD8
+
 cells, indicating both are CD8 
dependent. Both groups that had been depleted of CD4
+
 cells began to trend toward significant 
loss of tumor control in the late stage tumors (Figures 11b-c). This may be indicative of CD4
+
 T 
cells being necessary for CD8
+
 development of memory for long term responses, which will be 
investigated further. 
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Figure 11 | Tumor control elicited by neoepitopes are CD8 dependent 
a. Experimental scheme: Mice were immunized with neoepitopes 2 days after receiving 250µg of either αCD4, 
αCD8 depleting antibody or the isotype control αLTF2 antibody. 100µg of depletion antibodies were continued  to 
be administered once every week until the mice were euthanized. b. The average tumor growth curves for BDMCs, 
peptide 261 and peptide 209 groups. Means ± s.e.m. shown.  c. TCI scores are represented for the each of the 
vaccine groups and subdivided into their depletion groups. Means ± s.d. shown. (b.c.) n=10 mice/ group; *p<0.05 
(Student’s t-test). 
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Cox6a2 and Fam171b precise peptides 
The peptides used for immunization are processed and presented by the antigen presentation 
machinery, and the precise neoepitopes of the 21mer used for immunization was not known. In 
an attempt to accurately identify the precise epitope of Cox6a2 and Fam171b that is presented by 
the tumor and/or the BMDCs, I tested the top two precise peptides that have the highest 
predicted binding affinities to H-2K
b
 and H-2D
b
. The predicted binding affinities of the epitopes 
are shown in the tables below Figure 12a. The second highest predicted epitope for H-2K
b
 of 
Cox6a2, labeled Kb2, and the highest predicted binder for H-2D
b
 of Fam171b, labeled Db1, 
consistently showed significant tumor control as compared to their other putative precise 
neoepitopes (Figure 12a). I conclude that these are the two major precise neoepitopes presented 
after processing and are responsible for the tumor responses. 
 
Molecular modeling of MHC class I- peptide interaction 
In order to understand the characteristics of these two neoepitopes that contribute to their 
immunological properties, extensive molecular modeling was conducted for the identified 
precise peptides and their predicted cognate MHC class I allele. Low-resolution centroid 
modeling was followed by high-resolution refinement and then repeated 10,000 times to find the 
highest likely conformation of the neoepitope and its wild type counterpart. PCA analysis was 
conducted on density-based spatial clustering of applications with noise (DBSCAN) to find the 
modeled populations with the favorable lowest energetic scores. The final conformations can be 
seen in Figure 12b. Cox6a2’s neoepitope results in a completely different conformation than its 
wild type counterpart. Modeling suggests that replacing the p5 proline with a histidine allows the 
neoepitope to adopt a more compact backbone conformation in the binding groove, thus the 
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surface presented to a TCR differs considerably compared to the wild type. On the other hand, 
modeling Fam171b neoepitope behaved almost identical to the wild type peptide adopting the 
same conformation, but the neoepitope is presented more stably. This is similar to the 
conclusions drawn in the neoepitopes described in Duan et al. 2014
38
, where a more ridged c 
terminus than its wild type counterpart results in a favorable neoepitope. 
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Figure 12 | Precise peptides for Cox6a2 and Fam171b 
a. The two predicted highest binding affinity precise peptides for both H-2K
b
 and H-2D
b
 were used to immunize mice followed by tumor 
challenge. The upper figures show the average tumor growth curves for BDMCs only compared to the four precise peptides. Means ± s.e.m. 
shown. ; n=5 mice/group. *p<0.05 (Student’s t-test). The lower tables represent the peptide sequence, the predicted IC
50
 scores (nM) for the 
stated MHC I, and DAI scores. All predicted using NetMHC4.0. b. Molecular modeling was performed for the precise neoepitopes that showed 
a significant tumor response. Low-resolution centroid modeling was followed by high-resolution refinement and then repeated 10,000 times to 
find the highest likely conformation of the neoepitope and its wild type counterpart. PCA analysis was conducted on density-based spatial 
clustering of applications with noise (DBSCAN) to find the modeled populations with the favorable lowest energetic scores. Differences were 
also quantified by superimposing average peptide conformations from the molecular dynamics simulations and computing RMSDs for all 
common atoms. Cox6a2 was modeled for H-2K
b
 (left) and Fam171b was modeled for H-2D
b 
(right). 
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Chapter 4 
 
 
Plasticity of effector T cell phenotypes elicited by 
neoepitopes  
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Introduction 
A major hurdle for cancer immunotherapies is overcoming the suppressive tumor environment 
and avoiding peripheral tolerization. Tumor specific T cells take on an exhausted phenotype, and 
recent efforts to overcome this exhaustion has been with checkpoint inhibitors, mainly αCTLA-
4, αPD-1 and αPDL1. The idea behind these treatments is that by targeting the co-inhibitory 
molecules CTLA-4 and PD-1 found on T cells, the inhibitory signaling or “brakes” can be 
removed from these cells thus generating a stronger anti-tumor response
92,93
. Many studies have 
had positive outcomes and have demonstrated their efficacy
94–98
.  However, these responses 
remain limited to only a subset of patients, which can differ significantly between tumor types. 
This complexity has been demonstrated not only in the significant disparities between different 
tumor types but further as the vast heterogeneity within a single patient’s lesion(s)89.  Numerous 
factors such as differences in tumor cell clonality, immune cell infiltration, angiogenic factors, 
mutational burden, etc. contribute to treatment response and ultimately determine treatment 
outcomes. The critical factor for selecting neoepitopes for therapy is to select neoepitopes that 
can avoid/overcome this peripheral tolerance and exhaustion. 
 
In addition to immune checkpoint ligand expression, T cells that have become exhausted have 
distinct genetic patterns.  Studies by Ahmed et al have identified molecular signatures of CD8
+
 T 
cell exhaustion in chronic viral infections
126
, and many of the same phenotypes are observed in 
tumor specific CD8
+
 T cells. It is important to understand when tumor specific T cell exhaustion 
occurs, and specifically what phenotypes are more prone to suppression during tumor 
development. Work by Schietinger et al  has demonstrated that tumor specific T cell dysfunction 
occurs early in tumor progression
127
, and  recent work by her group has characterized these T 
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cells that have a fixed chromatin state that are unable to be rescued
128
. These T cells can be 
broadly identified by the expression of  PD1
hi
LAG3
hi
CD38
hi
CD101
hi
 on the cell surface. In 
contrast, they had also identified T cells within the tumor, PD1
hi
LAG3
hi
CD38
lo
CD101
lo
, that 
maintain a plastic reprogrammable phenotype. A major known driver of T cell exhaustion is the 
level T cell receptor (TCR) stimulation. It is well established that a high TCR avidity
129–131
  and 
antigen concentrations
132,133
 can drive an exhausted and dysfunctional phenotype. Through 
targeting neoepitopes that result in low avidity T cells and selecting the right antigen dose, it will 
elicit a robust effector T cell response within the tumor and avoid tolerization. 
 
In the chapter of my thesis, I will discuss our preliminary experiments investigating which CD8 
T cell response is ideal for a tumor rejection neoepitope. I hypothesize that through 
characterizing the neoepitope specific CD8 T cell response that results in tumor rejection, we can 
then pre-screen our neoepitopes to select the strongest candidates based on activated CD8 
markers that we identify. 
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Results 
Cox6a2 and Fam171b CD8
+
 TILs are in a favorable plastic phenotypic state 
In order to elucidate how these weak MHC class I binding neoepitopes are resulting in 
significant tumor control, I analyzed the tumor infiltrating lymphocytes (TILs) from the mice 
immunized with these neoepitopes (Figure 13a). I compare the neoepitope vaccines with 
BMDCs alone and peptide 244 (Figure 13b). Peptide 244 is predicted to bind MHC class I with a 
high affinity and had a significant CD8
+IFNγ response against MC38-FABF immunized mice, 
but showed no response in tumor control studies. Mice were immunized with BMDCs alone or 
one of the three peptides and then tumor challenged. On day 25 post tumor challenge, tumors 
were harvested and CD8
+
 TIL were isolated. At this time point, Cox6a2 and Fam171b mice 
controlled the growth of the tumors, and the other groups’ tumors had escaped (Figure 13c).  
Flow analysis on CD8
+
 TILs isolated from tumors revealed that Cox6a2 and Fam171b 
immunized mice have significantly lower levels of CD38 expression on CD8
+
PD-1
high
LAG3
high
 
cells (Figure 13d). This phenotype described by Philip et al. has a plastic and reprogrammable T 
cell state that is favorable for eliciting a robust tumor response
128
. Tumors from BMDC only and 
244 mice showed high levels of CD38 on the same cell subset, which is indicative of an 
exhausted and fixed state of the T cells. Consistent with an overall lower exhausted state of the 
tumor rejecting neoepitope groups, TIM3 and 2B4 MFI is significantly lower than the controls
134
 
(Figures 13e-f). Indicative of a strong T effector response, the TIL of the neoepitopes had 
significantly lower levels of CD62L than the controls, hinting that they are likely more of an 
effector memory phenotype
135
 (Figure 13g). Consistent with a plastic/reprogrammable 
phenotype, a key regulator of T cell differentiation, TCF1, was significantly higher for Cox6a2 
and Fam171b, which corresponds with their lower CD38 expression
136
 (Figure 13h). Based on 
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this data, I hypothesize that Fam171b and Cox6a2 result in an overall lower TCR stimulation, 
but strong enough to elicit an effector T cell response that avoids T cell exhaustion and 
dysfunction in the tumor microenvironment. Therefore, this allows for an effective neoepitope 
that elicits strong tumor response.  
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Figure 13 | CD8+ TIL from tumors of mice immunized with Cox6a2 and Fam171b have a more plastic and less exhausted phenotype 
a. Experimental scheme. b. The table contains TCI scores, gene names, binding affinities, and immunogenicity measure via ELISpot for the 
three peptides used for immunizations where TILs were analyzed. Binding affinity scores were predicted using NetMHC4.0. ELISpot 
immunogenicity was determined from figure 8 where MC38-FABF immunized mice were tested for immune responses against all peptides. 
(≤0 spots/10
6
 CD8
+
 cells=-, 0-50 spots/10
6
 CD8
+
 cells=++, >140 spots/ 10
6
 CD8
+
 cells =++++). c. Average tumor growth curves for 
designated groups, with final measurement the same day as TIL harvest. Means ± s.e.m. shown. ; n=5 mice/group.  d-h. Flow analysis of day 
25 CD8
+ 
TIL from designated groups. Mean fluorescence intensity shown ± s.d.; n= 5 mice pre group, *p<0.05 (Student’s t-test). (d) Gated on 
CD8
+
PD-1
high
LAG3
high
. (e-h) Gated on CD8
+
. This experiment has only been completed once, and is currently being repeated. 
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Chapter 5 
 
 
Discussion 
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In this study, I identified nine neoepitopes out of 279 SNVs tested that were able to elicit 
significant tumor protection.  It is important to note that not a single neoepitope(s) vaccine was 
capable of complete rejecting all tumors for a given group as well irradiated tumor cells. This 
may be indicative that neoepitopes may not be sufficient alone to reject aggressive solid tumors. 
Combination with other adjuvants, checkpoint inhibitors, or other treatments may be necessary to 
achieve complete protection. Ongoing studies are being conducted to enhance the tumor 
rejection in combination with other treatments and vaccine strategies, and to further investigate 
why vaccination with irradiated tumor cells provide complete protection.  
 
Since I observed that peptide combinations can have varied effects compared to single peptides, 
it will be important to us to test the remaining 159 peptides from the groups that did not show a 
positive TCI score. Although, I believe our screening strategy did lead us to identifying the top 
nine neoepitopes for MC38-FABF, because the combination of the nine in one vaccine 
outperformed all other vaccines tested, including all 279 peptides in one vaccine. I have 
demonstrated the importance of the combination of multiple neoepitopes into a vaccine to elicit 
the most robust response. This will be important for natural tumors where heterogeneity and 
antigen escape play a major role in efficacy. 
 
When measuring potential neoepitope efficacy and response in the clinical setting, the vast 
majority of studies have relied on the measurable T cell response ex vivo. Our study 
demonstrates that a measurable CD8
+
 T cell response is not indicative to tumor control. Only two 
of our top nine neoepitopes had a significant CD8
+IFNγ response measured via ELISpot, which 
is thought to be the most sensitive screening assay. I know that the tumor responses are CD8 
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dependent, because when I deplete CD8
+
 cells from the mouse, I completely ablate protection of 
our top two neoepitopes Cox6a2 and Fam171b. The tumor response is not lost with CD4
+
 
depletion. This may be indicative that our T cell assays are not sensitive enough to measure 
neoepitope specific responses. This may be because neoepitope specific T cells that reject tumor 
successfully do not elicit as robust of a response as viral and model antigen T cells, which will be 
discussed further later on.  
 
Most neoepitope selection pipelines use a 500 nM binding affinity threshold of an antigen to its 
cognate MHC class I, and only select the top binders for vaccination. In our study, only two of 
our nine neoepitopes have a predicted moderate and strong binding affinity, where only one is 
within the top 10% of predicted binders. The top performing neoepitopes are considered weak 
binders, and normally would be overlooked. This corresponds with the data from the Sahin et al 
trial where ~20% of immunogenic neoepitopes were predicted weak binders for MHC class I and 
II
123
. Predicted binding affinity of a neoepitope to its cognate MHC class I is not a predictor of 
tumor response. This may be indicative that our prediction algorithms are not accurate, but 
ongoing binding affinity measurements will clarify this discrepancy. Early indication that I was 
unable to synthesize tetramers (data not shown) hints that these truly are weak binders. I must 
identify further criteria beyond binding affinity predictions when selecting neoepitopes. 
 
Our top two neoepitopes Cox6a2 and Fam171b were capable of significantly controlling tumor 
growth compared to their wild-type counterparts and prolong the survival of the mice. These 
neoepitopes were also demonstrated to be effective in a therapeutic model system. Further 
confirming that neoepitope combination is more beneficial, the combination of Cox6a2 and 
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Fam171b showed significant tumor control and especially in the therapy model where it 
outperformed the individual peptides in tumor growth control and survival. The precise peptides 
were identified for each, and both had predicted binding affinities >7000 nM for H-2K
b
 and H-
2D
b
. Both had a positive DAI score, confirming that the stronger mutant peptide than its wild-
type counterpart is necessary for tumor protection.  
 
Molecular modeling of Cox6a2 and Fam171b suggests two main conformation ideologies. 
Cox6a2’s proline to histidine mutation at position five results in a completely different 
conformation of the peptide within the binding groove of MHC class I. The backbone mutation 
causes a favorable conformation that inverts the peptide in the groove, and exposes a 
hydrophobic residue to the TCR. This would increase the overall TCR avidity
137
 and would be 
presented as a completely foreign antigen compared to the wild-type. Fam171b on the other hand 
has a c-terminus mutation that does not alter the conformation of the peptide in the binding 
groove. The arginine to methionine substitution at p9 is favorable to the binding of the c-
terminus in the binding groove, and results in a more stable peptide than the wild type. This 
observation was made previously in the neoepitopes identified in Duan et al when the DAI 
predicted neoepitopes had a favorable rigid c-terminus
38
. 
 
When investigating CD8
+
 TIL from tumors of mice immunized with either the protective 
neoepitopes or a non-tumor protective high affinity immunogenic peptide, preliminary studies 
are consistent with the idea that the response the neoepitopes were inducing was favorable for 
tumor protection. Cox6a2 and Fam171b immunized mice have significantly lower levels of 
CD38 expression on CD8
+
PD-1
high
LAG3
high
 cells. This phenotype is indicative of a plastic and 
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reprogrammable T cell that has not undergone exhaustion. They also had lower levels of CD62L 
and higher levels of TCF1, which further confers with a plastic effector response
135,136
. The 
peptide that was unable to reject tumor had high levels of CD38 and exhaustive markers, such as 
TIM3 and 2B4. Even though this peptide elicited a robust T cell response ex vivo, it is likely that 
these T cells are quickly suppressed in the tumor microenvironment and become exhausted. 
Ongoing and future experiments will continue to examine the phenotype of the TIL from these 
mice and the other seven neoepitopes identified. I will also investigate the co-inhibitory markers 
identified in the recent study of Chihara et al, that studied the transcriptional regulation of 
dysfunctional T cells, and identified new markers of an exhaustive phenotype
138
. 
 
Taking all the data into consideration, I have identified mainly predicted weak affinity 
neoepitopes to MHC class I that cause significant tumor control and maintain a plastic effector 
phenotype within the tumor. I hypothesize that the overall avidity of the pMHC interaction with 
the TCR is the major factor that regulates this response. It has clearly been demonstrated that 
overstimulation of a high avidity T cells leads to an impaired response
129
. A study by Pace et al 
demonstrated that when mice were depleted of T regulatory (Treg) cells, it allows for the 
expansion of low avidity effector T cells
139
. In our model systems, our mice are receiving 
αCTLA-4 which is known to deplete Treg cells
140
 in the tumor, which would already make the 
tumor environment preferential to the expansion of low avidity T cells based on the observations 
of Pace et al. A major contributor to the overall avidity, other than TCR affinity, is the peptide 
binding affinity to MHC. I hypothesize that a weak pMHC interaction can lead to an overall 
lower avidity T cell interaction, but strong enough overall avidity to generate an effector T cell 
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response. If I am able to clone out neoepitope specific T cells in our model, I can then begin to 
test this hypothesis.  
 
In Figure 14, I demonstrate our working hypothesis for selecting the best candidate neoepitopes. 
The T cell repertoire is shaped via central tolerance and peripheral tolerance. T cells are deleted 
from the repertoire due to a high affinity for endogenous antigen or due to neglect. Of the 
remaining repertoire, if a T cell avidity is too high it leads to tolerization and exhaustion within 
the tumor environment; as observed with peptide 244. A high binding affinity of a peptide to 
MHC class I will likely result in an epitope that is stable and expressed in high levels on the cell 
surface. This high expression and stability would allow for an overall higher avidity with the T 
cells. Because I see a strong immune response ex vivo, but no tumor response and an exhausted 
phenotype to these antigens, I believe the high avidity interactions are being tolerized rapidly 
within the tumor. I hypothesize that through identifying the neoepitopes that contribute to an 
overall lower avidity but strong enough to elicit a response, we can begin to understand what 
makes a strong candidate neoepitope. I believe that the pMHC affinity is a major contributor to 
overall avidity, and can be used for selecting neoepitopes. This is supported by the observation 
that the neoepitopes I identified in this study mainly have a weak to moderate binding affinity 
and a positive DAI.  
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Figure 14 | Working theory for targeting tumor rejecting neoepitopes 
This figure represent the working hypothesis for selecting the best neoepitopes for personalized cancer immunotherapies. 
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